Background: Traditionally, metastatic colorectal cancer (MCRC) has been treated with intravenous (i.v.) 5-fluorouracil/leucovorin (5-FU/LV ). The tumour-activated, oral fluoropyrimidine capecitabine demonstrates superior activity and favourable safety compared with the Mayo regimen, while potentially avoiding the complications and inconvenience associated with i.v. regimens.
introduction
The outcomes of cancer therapy are traditionally evaluated using objective response and survival criteria. There is, however, increasing emphasis on assessment of quality of life (QoL), convenience and patient preference. For many years, metastatic colorectal cancer (CRC) has been treated primarily with either bolus or infused intravenous (i.v.) 5-fluorouracil (5-FU), with or without leucovorin (LV). As well as impacting significantly on often over-stretched resources, i.v. chemotherapy is inconvenient for patients and may be associated with pain, discomfort and complications such as thrombosis, bleeding and infection [1] [2] [3] [4] [5] [6] [7] [8] , particularly with regimens requiring indwelling i.v. catheters for continuous or protracted infusion. In addition, i.v. chemotherapy may be associated with significant psychological distress, prolonged hospital stays and financial burden [9] .
Home-based treatment may improve QoL, decrease analgesic requirements and reduce psychosocial morbidity compared with hospital-based therapy in patients with advanced cancer [9] [10] [11] . However, the ambulatory pumps used to facilitate home-based administration of i.v. 5-FU regimens still require indwelling i.v. catheters with the potential for discomfort and significant complications [2] . Indeed, a recent literature review showed that symptomatic central venous catheter (CVC)-related deep-vein thrombosis (DVT) occurred in up to 28% of patients receiving chemotherapy via CVCs [7] .
Oral chemotherapy offers several potential advantages, with improved convenience and less impact on the patient's lifestyle compared with i.v. treatment. Capecitabine has become a well-established alternative to i.v. 5-FU/LV in the treatment of metastatic CRC. An oral fluoropyrimidine, it is designed to generate 5-FU preferentially in tumour tissue, exploiting the increased expression of thymidine phosphorylase in tumours compared with healthy tissue [12, 13] .
Two large, phase III studies (n = 1207) demonstrated that, as first-line therapy for metastatic CRC, capecitabine achieves superior antitumour activity with a favourable safety profile compared to i.v. 5-FU/LV (Mayo Clinic regimen) [14, 15] . The improved efficacy and safety profiles of capecitabine were also mirrored in the adjuvant setting, where capecitabine showed a consistent (4%) improvement in disease-free, relapse-free and overall survival compared with 5-FU/LV (Mayo Clinic regimen) [16, 17] . Furthermore, medical resource use is reduced with oral capecitabine when compared with i.v. 5-FU/LV (Mayo Clinic regimen) in both the adjuvant and metastatic settings, with reduced costs for management of adverse events and fewer ambulatory visits [18, 19] . A recent pharmacoeconomic analysis showed that capecitabine is a 'dominant strategy' compared with i.v. 5FU/LV in the adjuvant treatment of colon cancer, providing superior outcomes with cost savings versus the Mayo Clinic Regimen [20] . Capecitabine also saves staff time compared with infused 5-FU. A UK time-and-motion audit showed that combined staff time for administration and consultation was more than 10-fold greater with the modified de Gramont 5-FU/LV regimen than with capecitabine (mean time per course of treatment: 669 min versus 60 min, respectively) [21] .
In a recent study, patients who had received both the Mayo Clinic regimen and the oral fluoropyrimidine UFT expressed a strong preference for oral treatment [22] , while a previous questionnaire-based study showed that oral treatment was strongly preferred provided that this was not at the expense of efficacy [23] . However, in the metastatic setting, infusional 5-FU regimens have largely replaced bolus 5-FU/LV, especially in Europe, and patients' preference for oral treatment compared with an infusion regimen has not previously been evaluated.
The current open-label, randomised, cross-over study was conducted to determine patient preference for treatment with capecitabine or an i.v. 5-FU/LV regimen (the bolus Mayo Clinic regimen or the infusional de Gramont regimen, administered on either an in-or out-patient basis) in patients with advanced CRC. Secondary objectives of the study were toxicity, QoL and patient satisfaction with treatment, which may underpin or influence preference for a particular regimen.
patients and methods patients
Male and female patients aged between 18 and 75 years with previously untreated advanced or metastatic CRC were eligible for the study. In addition, they were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of £2 and life expectancy of at least 3 months. Any prior adjuvant chemotherapy was to have been completed at least 6 months before enrolment. Patients were required to have an absolute neutrophil count ‡1.5 · 10 9 /l, platelet count ‡100 · 10 9 /l, haemoglobin >8 g/dl, corrected serum calcium <2.80 mmol/l and bilirubin £1.5· upper normal limit.
The following patients were excluded from study: pregnant or lactating patients, those who had previously experienced a severe and unexpected reaction to fluoropyrimidine therapy or with known hypersensitivity to 5-FU, patients with severe renal impairment (creatinine clearance £30 ml/ min according to the Cockcroft-Gault formula), central nervous system disorders or psychiatric disability, clinically significant cardiac disease, arrhythmias or angina pectoris. Patients with serious, uncontrolled, intercurrent infection and those known to have hepatitis B or C, or human immunodeficiency virus infection were also ineligible. Patients with malabsorption syndromes or a history of previous gastrointestinal surgery affecting oral absorption were also excluded from study, as were patients with a history of another malignancy within the previous 5 years, except successfully treated basal cancer of the skin or carcinoma in situ of the uterine cervix. Participation in any study of an investigational drug within the 4 weeks prior to study also precluded enrolment.
The study was conducted in accordance with local ethical and regulatory requirements and all patients provided written informed consent.
study treatment
In this study, treatment with capecitabine was compared with the i.v. 5-FU/LV treatment regimen that was used routinely in each participating centre (Mayo Clinic and in-or out-patient de Gramont regimens) to reflect standard clinical practice. The treatment scheme for the study is shown in over 46 h [24] . Dose modification for management of adverse events was conducted according to the local practice of the participating centres and capecitabine dose modification guidelines [15] . Administration of additional cytotoxic agents or investigational drugs was prohibited during study. Patients received supportive therapy according to standard practice at their centre. original article
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Patient preference was assessed using a questionnaire designed specifically for this study. The preference questionnaire was distributed by clinic staff and completed by each patient, without assistance, prior to the first dose of study drug and on the last day of the second course of treatment (Table 1) .
Results from the patient preference questionnaire were analysed using the Hills-Armitage approach [25] , which excludes patients who expressed 'no preference' from the analysis. A 2 · 2 table of association was then constructed and the associations of treatment sequence and preferences tested using Fisher's exact test. Patient satisfaction with treatment was assessed using a questionnaire designed for use in this study and completed by each patient on the final day of the second course of treatment. Patients were asked to rate, on a scale of 1 (very dissatisfied) to 10 (very satisfied), both the regimens in terms of overall satisfaction, convenience and how they felt after treatment. For each patient, the difference in the ratings for each period was calculated and all patients were ranked in order. The Mann-Whitney U-test was applied to the period differences in overall satisfaction between the oral and i.v. regimens. A positive estimated score indicated increased overall satisfaction with oral compared with i.v. therapy and a negative score indicated increased overall satisfaction for i.v. compared with oral therapy.
QoL was assessed using the validated FACT-C questionnaire [26] prior to randomisation, and on the final days of the first and second courses of treatment. Overall QoL scores were evaluated using an analysis of variance and estimates of treatment effects were presented for each group adjusting for sequence group, treatment and period. A positive score indicated increased QoL with oral compared with i.v. therapy and a negative score demonstrated increased QoL with i.v. compared with oral therapy.
Safety was evaluated in all patients receiving at least one dose of study treatment. Adverse events were graded according to the National Institute of Cancer (NCI) Common Toxicity Criteria (CTC) version 2 until 4 weeks after last study drug administration.
results

patient population and disposition
In total, 97 patients from 13 centres in the UK were enrolled and of these, 94 were evaluable (prior to receiving treatment one patient died, one had no i.v. access and was excluded, and one withdrew from the study). The uneven weighting in the IPdG arm, shown in Figure 2 , was due to a randomisation error in a single centre (of the 44 patients on the IPdG arm, 26 received the oral/i.v. sequence and 18 the i.v./oral sequence; four patients were allocated to the sequence different from that to which they were originally randomised). Recruitment to this arm of the study was increased in an attempt to redress the imbalance. All patients were analysed according to the regimen/ sequence actually received.
The baseline characteristics of patients are shown in Table 2 , including initial treatment preferences in the three arms. A higher proportion of patients in the Mayo Clinic regimen arm had an ECOG performance score of 0 compared with those in the de Gramont regimen arms (58% versus 30% and 37% for the IPdG and OPdG arms, respectively). Also, a higher proportion of males (81%) received the OPdG regimen compared with the other 5-FU/LV regimens (58% in both the Mayo and IPdG regimen arms). The median age of patients receiving the de Gramont regimens was older than in the Mayo Clinic group.
treatment preferences before and after treatment
The results of the treatment preference questionnaires are shown in Table 3 . Almost all patients (98%) completed the patient preference questionnaire prior to the first dose of study drug. Overall, before treatment, 78% of patients completing questionnaires expressed a preference for oral therapy, 4% for i.v. and 18% were undecided. Therefore, of those patients who expressed a particular preference, 95% preferred oral and 5% preferred i.v. regimens prior to treatment. Patient preference questionnaires were completed by 76% of patients after treatment course 2 (Table 3) . For patients who did not complete post-treatment questionnaires, the principal causes (80% of cases) were early death or withdrawal due to adverse events. Figure 3 shows that, after receiving both treatment courses, the preference for oral therapy was maintained by the majority of patients. Overall, 57% of patients expressed a preference for capecitabine and 32% for 5-FU/LV. Again, of those for whom a preference was recorded, 64% preferred oral and 36% preferred i.v. therapy. The type of i.v. regimen administered did, however, influence this preference to a large degree. Following treatment, of those who expressed a preference, an equal proportion (50%) of patients receiving the OPdG regimen preferred i.v. and oral treatment; a higher proportion of patients preferred capecitabine to IPdG (63%) or Mayo Clinic (86%) regimens (Table 3, Figure 3 ). In the Mayo Clinic and IPdG groups, the three patients who expressed a preference for i.v. administration before treatment reported a preference for oral administration after the second treatment period. The principal reasons given by patients for preferring a particular regimen after treatment are illustrated in Figure 4 . For the 42 patients who preferred capecitabine after treatment, the convenience of tablet administration at home was the dominant rationale. Where i.v. therapy was preferred (24 patients), the principal reason was that it caused fewer side-effects. The order in which treatment was received did not appear to influence treatment preference (data not shown).
treatment satisfaction
Patient satisfaction with treatment was assessed on the last day of treatment course 2. A positive score indicates increased satisfaction with oral compared with i.v. therapy and a negative score indicates increased satisfaction for i.v. compared with oral therapy.
Overall, there was no difference in patient satisfaction with oral or i.v. therapy (Table 4) . However, results varied across the different i.v. regimens. Although the number of patients analysed was small, it appeared that treatment satisfaction with capecitabine was higher than with the Mayo Clinic regimen (P <0.05). No significant difference in patients' median treatment satisfaction scores was observed between capecitabine and the IPdG regimen. In contrast, treatment satisfaction with the OPdG regimen appeared higher than with capecitabine (P <0.05). 2 (17) 3 (25) 7 (28) 6 (33) 4 (29) 1 (8) a Thirteen patients were randomised but one died prior to treatment and did not complete a questionnaire. Overall, mean QoL scores were maintained throughout the study period in all groups. Although the number of patients analysed was small and time over which the assessment was made was short, no differences in estimated QoL scores were observed between patients receiving capecitabine and those receiving the Mayo Clinic or IPdG regimens (Table 5) . Mean QoL scores appeared higher with the OPdG regimen compared with oral therapy (P <0.05).
toxicity
The small number of patients in the individual i.v. treatment groups precluded formal comparison of toxicity in each arm. Treatment-related adverse events (all grades) were observed in 60% of patients when receiving both capecitabine and i.v. 5-FU/ LV. In all arms, treatment-related adverse events were typical fluoropyrimidine toxicities. Grade 3/4 adverse events were uncommon in all treatment arms, occurring in 12% and 7% of patients during treatment with capecitabine and i.v. 5-FU/LV, respectively ( Figure 5 ). No substantial differences in the safety profiles of the regimens were observed with the different treatment sequences.
discussion
The improved antitumour activity, favourable tolerability, improved medical resource utilisation and pharmacoeconomics of capecitabine compared with 5-FU/LV lend support to its increasing use for the treatment of advanced CRC [20, 27] . Capecitabine also appears more convenient for patients, but it is important to confirm this by analysing patient preference and treatment satisfaction. Although previous studies have demonstrated that patients prefer oral compared with i.v. chemotherapy [22, 23] , the current study represents the first formal evaluation of patient preference for oral capecitabine versus both bolus and infusional i.v. 5-FU/LV regimens. Before treatment, the majority of patients expressed a preference for the oral therapy, citing increased convenience, administration at home and an oral administration route as the main reasons for their initial preference. These reasons were also prominent in a study by Liu et al. [23] , which also demonstrated that patients are unwilling to accept a reduction in efficacy. The current study was not designed to compare efficacy; however, capecitabine has been shown to achieve significantly higher response rates than bolus 5-FU/LV as first-line therapy for metastatic CRC [14] . Infusional 5-FU/LV also achieved higher response rates than bolus 5-FU/LV [28] , but neither capecitabine nor infusional 5-FU/LV significantly prolonged survival. It is most likely, therefore, that capecitabine and infusional 5-FU/LV have very similar activity and are both at least as effective as bolus 5-FU/LV [27] .
In the current study, the majority of patients who preferred oral therapy before treatment maintained their preference after treatment, usually because of the greater convenience of treatment at home. Following treatment, the preference for oral therapy (86%) was strongest in patients for whom the alternative was bolus 5-FU/LV, with only two patients preferring the Mayo Clinic regimen over capecitabine. There was also a clear, though less marked, preference for capecitabine (63%) over the IPdG infusion regimen. Those patients receiving oral capecitabine and the OPdG infusion regimen were equally split in terms of their preference. The variation in expressed preference for oral therapy in relation to the nature of the i.v. treatment may be due to a variety of factors. The Mayo Clinic regimen requires frequent hospital visits and is less well tolerated than the IPdG regimen in terms of toxicity profile [28] . The OPdG regimen has the advantage to the patient that disconnection of the 46-h 5-FU infusional pump and the second week central line flush can be carried out in the patient's home, with less inconvenience for the patient and only one hospital visit every 14 days. Nearly half the patients in the OPdG arm who initially expressed a preference for oral treatment later changed that preference, with most stating that i.v. therapy caused few side-effects. The OpdG regimen is clearly a reasonable option for many patients. However, it also emphasises the importance of educating patients and healthcare staff in the prevention of toxicity associated with capecitabine if patients are to benefit from the convenience of oral therapy.
Patients appeared least satisfied with the Mayo Clinic regimen versus oral treatment, particularly when they received oral therapy first. This is consistent with previous studies demonstrating increased levels of treatment satisfaction from home-based compared with hospital-based therapy [29, 30] . There was a trend towards increased satisfaction with the IPdG regimen and a statistically significant increase in satisfaction with the OPdG regimen over capecitabine. This may be explained by the low toxicity and increased convenience of the OPdG regimen or may conceivably be a consequence of the poorer baseline performance status and greater age of patients receiving the de Gramont regimens. A higher percentage of patients in the de Gramont arms had ECOG performance status of 1/2, and their median age was higher than those receiving the Mayo Clinic regimen. It is possible that more frail patients may appreciate close and immediate access to medical support and prefer the responsibility for administration of i.v. chemotherapy to rest in the hands of their health professionals. The QoL analysis failed to demonstrate any statistically significant difference between capecitabine and either Mayo Clinic or IPdG regimens. In contrast, the OPdG regimen showed a statistically increased QoL benefit compared with capecitabine (P < 0.05). The apparent preference for the OPdG regimen compared with capecitabine in terms of patient satisfaction estimates and QoL is perhaps surprising given that the results from the patient preference assessments showed an equal split between OPdG and capecitabine. The apparent differences between the different i.v. regimens in terms of patient satisfaction and QoL scores should, however, be interpreted with caution because of the small and variable proportion of patients completing questionnaires and the limited period over which the data were collected. Nevertheless, the demonstrated benefit of patient choice in the cancer treatment decision-making process supports an option for patient choice in the management of advanced CRC [31] . These data indicate that, prior to receiving chemotherapy, oral treatment is the preferred choice for the majority of patients with advanced CRC, mirroring the results of a previous study [23] . After experiencing both capecitabine and a variety of i.v. regimens, at least half the patients retained this preference, again in line with previous experience with another oral 
